Figure 4. Risk of composite cardiovascular and kidney outcomes associated with sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) continuation vs discontinuation by estimated glomerular filtration rate (eGFR) dipping category.

Model adjusted for both covariates measured at treatment initiation and characteristics evaluated within 6 months after treatment initiation. CVD indicates cardiovascular disease; and HR, hazard ratio.

^*Composite CVD outcome of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or all‐cause mortality. ^†Composite kidney outcome of eGFR decline >50%, end‐stage kidney disease, or all‐cause mortality.